QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis

Sunitinib is widely used as a first-line treatment for advanced renal cell carcinoma (RCC). However, a number of patients with RCC who receive sunitinib develop drug resistance; and the biological mechanisms involved in resistance to sunitinib remain unclear. It has previously been suggested that th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tangliang, Zhou, Yulin, Wang, Qingyun, Yi, Xiaoming, Ge, Silun, He, Haowei, Xue, Song, Du, Bowen, Ge, Jingping, Dong, Jie, Qu, Le, Wang, Linhui, Zhou, Wenquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208629/
https://www.ncbi.nlm.nih.gov/pubmed/34036385
http://dx.doi.org/10.3892/ijo.2021.5228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208629/
https://www.ncbi.nlm.nih.gov/pubmed/34036385
http://dx.doi.org/10.3892/ijo.2021.5228

Ejemplares similares